Novavax Inc vs Banco Santander SA — how do they compare? Novavax Inc trades at $7.97 (market cap $1.31B), while Banco Santander SA trades at $14.81 (market cap $211.63B). The key difference: Banco Santander SA is far larger — about 161.5× Novavax Inc's market cap, and Banco Santander SA pays a 1.89% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | SAN | |
|---|---|---|
Market Cap | $1.31B | $211.63B |
Sector | Health | Financials |
52-Week High | $11.19 | $14.71 |
52-Week Low | $6.22 | $9.37 |
Enterprise Value | $889.30M | — |
Dividend Yield | — | 1.89% |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Banco Santander (SAN) trades at $14.69, showing minimal daily movement with a slight decline of 0.07%. The stock maintains a bullish technical signal supported by moving averages, while oscillators indicate neutral momentum. Fundamentally, the company reported strong profitability with a 26.25% net income margin and record quarterly profits in Q2 2026. Recent developments include Federal Reserve approval for the $12 billion Webster Bank acquisition, positioning Santander for strategic expansion.
The outlook remains positive with analyst consensus favoring Buy ratings (64%) and the company achieving Spain's most valuable listed company status. Key risks include volatile cash flow trends with negative operating cash flow in 2024-2025 and restructuring charges from recent acquisitions. Revenue growth is projected to reach $61.9B in 2026, supporting continued investor confidence despite near-term earnings volatility.
Trailing returns across standard periods
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →